# 14.1.2 Fab Process Selection for iPACE-CHIP

## Overview

Selecting the fabrication process for the iPACE-CHIP medical implant is among the most
consequential decisions in the product development lifecycle. The process choice determines
performance boundaries, power consumption, die area, reliability characteristics, cost
structure, and supply chain flexibility. This chapter provides a systematic methodology
for evaluating and selecting the optimal fabrication process, with detailed analysis of
each candidate node and the trade-offs specific to implantable medical devices.

## Selection Criteria Framework

### Primary Requirements Hierarchy

The iPACE-CHIP fabrication process must satisfy constraints in a strict priority order:

1. **Patient Safety**: Thermal limits (ΔT < 1°C at tissue interface), biocompatibility
2. **Reliability**: 20-year operational lifetime, zero catastrophic failure modes
3. **Performance**: Neural signal bandwidth, stimulation accuracy, telemetry data rate
4. **Power Budget**: Total chip power < 10 mW, ideally < 5 mW
5. **Die Size**: Compatible with implant package constraints (< 25 mm² target)
6. **Cost**: Achievable at production volumes of 50,000-200,000 units/year
7. **Supply Chain**: Dual-source capability, geopolitical risk mitigation

### Medical Device Specific Constraints

Unlike consumer electronics, medical implant fabrication has unique requirements:

- **Process maturity**: Only qualified, high-volume nodes with extensive reliability data
- **Long-term support**: Process must remain active for 15+ years to support product lifecycle
- **Qualification history**: Existing medical device or military qualification base
- **Access to specialty options**: High-voltage, precision passive, NVM IP blocks
- **Wafer size compatibility**: 200 mm wafers preferred for cost-effective small-volume production

## Candidate Process Evaluation

### Node Comparison Matrix

| Parameter | 350 nm | 180 nm | 130 nm | 65 nm | 28 nm |
|-----------|--------|--------|--------|-------|-------|
| Digital Gate Density (Kgate/mm²) | 8 | 40 | 80 | 300 | 900 |
| Nominal VDD (V) | 3.3 | 1.8 | 1.2 | 1.0 | 0.9 |
| Static Power (Relative) | 10× | 1× | 0.5× | 0.3× | 0.2× |
| Analog Performance (gm/Id) | Excellent | Very Good | Good | Moderate | Poor |
| Max VDD for Analog | 5V | 3.3V | 2.5V | 1.8V | 1.5V |
| Process Maturity | 30+ years | 25+ years | 20+ years | 15+ years | 10+ years |
| Medical Qualifications | Extensive | Extensive | Good | Limited | Minimal |
| 200 mm Wafer Available | Yes | Yes | Yes | Some | No |
| Typical NRE | $0.5M | $1.5M | $3M | $8M | $25M |
| Die Cost (at 10mm²) | $2.50 | $3.00 | $4.50 | $8.00 | $15.00 |
| HV Transistor Available | Yes | Yes | Limited | No | No |
| High-Voltage Option | Up to 40V | Up to 20V | Up to 12V | N/A | N/A |

### Detailed Node Analysis

#### 350 nm Process

**Advantages**:
- Maximum design maturity with extensive medical device qualification history
- Highest analog transistor intrinsic gain (Early voltage > 50V)
- Widest voltage headroom for stimulation circuits (5V supply, 40V HV option)
- Lowest NRE cost enables rapid design iterations
- Most forgiving lithography reduces systematic yield loss

**Disadvantages**:
- Large die size increases per-unit cost and limits integration
- High dynamic power consumption at clock frequencies above 10 MHz
- Limited digital integration forces multi-chip solutions
- 200 mm wafer economics are marginal

**iPACE-CHIP Assessment**: Too large for full integration. Would require 50+ mm² die
area, exceeding implant package constraints. Consider only for prototype validation
of analog front-end performance.

#### 180 nm Process (SELECTED)

**Advantages**:
- Optimal balance of analog and digital capability
- Well-characterized process with 25+ years of production history
- Extensive medical device qualification base (pacemakers, neurostimulators)
- Available on 200 mm wafers from multiple foundries worldwide
- HV option (180HV) supports stimulation voltages up to 20V
- EEPROM and MIM capacitor options readily available
- NRE cost of $1.5M is manageable for medical device development budgets
- Die size for full iPACE-CHIP estimated at 8-12 mm² (fits package constraint)

**Disadvantages**:
- Higher dynamic power than advanced nodes at equivalent digital throughput
- Digital density limits on-chip memory to ~512 KB SRAM
- Not suitable for complex ML inference engines requiring billions of transistors

**iPACE-CHIP Assessment**: Selected as the primary fabrication process. The 180 nm
node provides sufficient digital integration for the RISC-V controller and support
logic while maintaining the analog excellence required for neural signal processing.
The mature process minimizes qualification risk and the 200 mm wafer base provides
supply chain flexibility.

#### 130 nm Process

**Advantages**:
- 2× digital density improvement over 180 nm
- Lower dynamic power at same clock frequency
- Enables more on-chip SRAM (up to 1 MB)
- Good analog performance, though reduced from 180 nm

**Disadvantages**:
- HV transistor options limited to 12V maximum
- Reduced analog headroom with 1.2V nominal supply
- Fewer foundries with medical device qualification at this node
- 300 mm wafer standard, increasing NRE and mask costs

**iPACE-CHIP Assessment**: Viable alternative if significantly more digital processing
is required in future iPACE-CHIP generations. The reduced HV capability limits
stimulation output options and requires careful analog design at 1.2V supply.

#### 65 nm and Below

**Advantages**:
- Massive digital density for complex SoC integration
- Very low power per gate for digital functions
- Enables on-chip ML accelerators

**Disadvantages**:
- Analog transistor performance degrades significantly
- No high-voltage transistor options
- Minimum supply voltages insufficient for stimulation circuits
- Qualification costs exceed $10M for medical applications
- Process characterization time exceeds 18 months
- 300 mm wafer only, no 200 mm option
- Few foundries support medical device programs at these nodes

**iPACE-CHIP Assessment**: Not suitable for current iPACE-CHIP generation. The
inability to integrate high-voltage stimulation circuits on advanced nodes would
require a separate stimulator die, increasing package complexity and interconnect
failure points. May become relevant for future digital-intensive processing
algorithms if implemented as a separate chiplet.

## Foundry Evaluation for 180 nm BiCMOS-SOI

### Candidate Foundries

| Foundry | Location | 180nm Options | Medical Qual | HV Available | SOI Available | Dual Source |
|---------|----------|---------------|-------------|-------------|--------------|-------------|
| TSMC | Taiwan | 180BCD, 180HV | Yes | Yes | No | Yes |
| GlobalFoundries | Germany/USA | 180HV | Yes | Yes | No | Yes |
| Samsung | Korea | 180BCD | Limited | Yes | No | Yes |
| Tower Semiconductor | Israel/USA | 180HV | Yes | Yes | Limited | Yes |
| X-FAB | Germany/Malaysia | XH018 | Yes | Yes | No | Yes |

### TSMC 180HV Evaluation

TSMC's 180HV process is the most widely used platform for medical device ASICs:

- **Process offerings**: 180nm standard, 180nm HV (18V), 180nm BCD (Bipolar-CMOS-DMOS)
- **Medical track record**: Qualified for numerous pacemaker and neurostimulator ASICs
- **Design ecosystem**: Mature PDK, extensive IP library, experienced design support
- **Yield history**: >98% D0 yield on 200mm wafers for medical designs
- **Qualification packages**: Pre-qualified HTOL, TC, HAST data available

### X-FAB XH018 Evaluation

X-FAB specializes in analog/mixed-signal and medical applications:

- **Process offerings**: XH018 with HV up to 18V, embedded NVM, MIM options
- **Medical track record**: Dedicated medical business unit with ISO 13485 support
- **European supply chain**: Provides geopolitical diversification from Asia-Pacific
- **Wafer size**: 200mm wafers, matching iPACE-CHIP requirements
- **Design support**: Application-specific PDK models for medical implants

### Selection Decision

**Primary foundry**: TSMC 180HV for production due to highest yield confidence, largest
design ecosystem, and broadest IP availability.

**Qualification foundry**: X-FAB XH018 as secondary qualification source, providing
supply chain resilience and European manufacturing option for data sovereignty
requirements.

## Process Design Kit (PDK) Requirements

### Model Requirements for iPACE-CHIP

The PDK must support the following simulation and verification needs:

**DC Models**: BSIM4 for CMOS, HICUM for BJTs, accurate across:
- Temperature: -40°C to +125°C (full military range)
- Voltage: 0V to VDD (nominal) + 10% (overdrive)
- Process corners: TT, FF, SS, SF, FS

**AC Models**: S-parameter and noise parameter files up to:
- 13.56 MHz (telemetry carrier frequency)
- 20 MHz (switching regulator frequency)
- 100 MHz (digital clock harmonics for EMI analysis)

**Noise Models**: Flicker noise (1/f) and thermal noise parameters validated against
measured silicon. The iPACE-CHIP front-end noise floor prediction must be accurate
to within 2 dB across the 1 Hz to 7 kHz neural signal band.

**Reliability Models**: Hot carrier injection, NBTI, TDDB, and electromigration
models calibrated to foundry reliability data. These are required for iPACE-CHIP
20-year lifetime projection.

### PDK Validation Checklist

| Item | Validation Method | Accept Criteria |
|------|------------------|-----------------|
| DC IV Curves | Match to foundry data at 3+ temps | < 5% error |
| AC Parameters | S-parameter simulation vs. data | < 1 dB at 13.56 MHz |
| Noise Parameters | Simulated vs. measured noise figure | < 1.5 dB mismatch |
| Breakdown Voltages | Simulated BV vs. specification | Within 5% |
| MIM Capacitor | C-V simulation vs. data | < 3% error |
| Resistor Models | R vs. T and R vs. V simulation | < 2% error |
| DRC/LVS Clean | Full-chip verification | Zero violations |

## Cost Modeling

### Die Cost Breakdown at 180 nm

For a 10 mm² die on 200 mm wafer at TSMC 180HV:

| Cost Component | Per Wafer | Per Die (280 dies/wafer) |
|---------------|-----------|--------------------------|
| Fab Processing | $3,000 | $10.71 |
| Mask Amortized | $1,500 | $5.36 |
| Test (Wafer Level) | $800 | $2.86 |
| Packaging (Hermetic) | $700 | $2.50 |
| Final Test | $500 | $1.79 |
| **Total COGS** | **$6,500** | **$23.21** |

### Volume Sensitivity Analysis

| Annual Volume | Die Cost | NRE Amortized (5yr) | Total Unit Cost |
|--------------|----------|---------------------|-----------------|
| 10,000 | $23.21 | $30.00 | $53.21 |
| 50,000 | $18.50 | $6.00 | $24.50 |
| 100,000 | $15.80 | $3.00 | $18.80 |
| 200,000 | $13.20 | $1.50 | $14.70 |

### Yield Impact on Cost

Yield is the dominant cost driver for medical device ASICs:

| Die Yield | Effective Die Cost | 100K Unit Cost |
|-----------|-------------------|----------------|
| 85% | $27.30 | $30.30 |
| 90% | $25.79 | $28.79 |
| 95% | $24.43 | $27.43 |
| 98% | $23.68 | $26.68 |
| 99% | $23.44 | $26.44 |

The iPACE-CHIP target yield of 98% on shipped die requires an initial wafer yield
above 95% before probe test screening.

## Technology Roadmap Considerations

### iPACE-CHIP Generation Planning

| Generation | Year | Process | Key Enhancement | Die Area |
|-----------|------|---------|-----------------|----------|
| Gen 1 | 2025 | 180nm | Baseline 8-ch stimulator | 10 mm² |
| Gen 2 | 2028 | 180nm | 32-ch, on-chip DSP | 14 mm² |
| Gen 3 | 2031 | 130nm | 128-ch, closed-loop | 12 mm² |
| Gen 4 | 2034 | 65nm | 256-ch, edge ML | 8 mm² |

### Migration Risk Assessment

Moving from 180 nm to 130 nm for Gen 3 carries the following risks:

- **Analog redesign**: All amplifier circuits require reoptimization for 1.2V supply
- **HV requalification**: Stimulation circuits limited to 12V, requiring electrode redesign
- **NRE impact**: $3M additional design cost, 18-month qualification timeline
- **Supply chain**: Qualify new foundry, potentially different packaging house

These risks are mitigated by beginning process development at TSMC 130nm in 2029,
allowing 2 years of qualification before Gen 3 production.

## Regulatory Implications

### FDA Process Validation Requirements

The FDA expects manufacturers to validate that the fabrication process consistently
produces devices meeting specifications. For the iPACE-CHIP 180 nm process:

**Process Qualification**: Complete IQ/OQ/PQ per 21 CFR 820.75
- Installation Qualification: Verify fab equipment meets specs
- Operational Qualification: Confirm process parameters within control limits
- Performance Qualification: Demonstrate die-level parametric yield meets targets

**Process Change Protocol**: Any foundry process revision requires:
- Risk assessment per ISO 14971
- delta-qualification (abbreviated reliability testing)
- FDA notification for Class III devices (PMA supplement)

**Statistical Process Control**: Monitor key parameters continuously:
- Transistor threshold voltage (Vt) mean and sigma
- Metal sheet resistance
- Contact/via resistance
- MIM capacitance density
- EEPROM endurance and retention

## Summary

The iPACE-CHIP fabrication process selection methodology balances patient safety,
reliability, performance, and cost through systematic evaluation of technology nodes,
foundry capabilities, and long-term supply chain considerations. The 180 nm BiCMOS-SOI
node, fabricated at TSMC as primary and X-FAB as secondary source, provides the optimal
solution for the current generation while establishing a clear migration path for future
enhancements. The rigorous PDK validation, cost modeling, and regulatory compliance
framework ensure that process selection supports the iPACE-CHIP zero-defect manufacturing
objective throughout the product lifecycle.

## References

1. TSMC 180nm Process Design Kit User Guide, Version 2024.1.
2. X-FAB XH018 Process Specification, Document No. XS1X0_0.
3. FDA Guidance: Process Validation — General Principles and Practices, 2011.
4. IEC 62304:2006+A1:2015, Medical Device Software — Software Life Cycle Processes.
5. iPACE-CHIP Product Requirements Document, Internal, Rev 2.1.
6. SEMI S2-0718, Environmental, Health, and Safety Guideline for Semiconductor Manufacturing.
7. McKinsey & Company, "Semiconductor Cost Modeling for Medical Applications," 2023.
8. B. Murphy, "Yield and Cost Optimization for Analog/Mixed-Signal ASICs," IEEE CICC, 2022.
